Akers Biosciences Share Discussion Threads

[rivaldo] 26/6/2015 12:36

Nice plug for AKR in the IC:



"Digital diagnosis

Digitising health is big business these days, and offers would-be biotech investors a de-risked model separate from more traditional drug development, albeit still at the forefront of the latest technology developments. This is particularly prevalent in the diagnostics market where better technology can deliver quick patient results at lower cost.

Akers Bioscience (AKR) makes single-use products that are designed to be used in vitro – outside of the body – to deliver accurate diagnostic results. Akers claims this could underpin a significant reduction on the cost of healthcare, particularly in the US, where healthcare reforms are amounting to soaring costs for the government.

The company’s BreathScan product is a breathalyser used to detect the amount of alcohol in a person’s system. It only requires four simple steps to use the device and takes just two minutes to generate results. While this is ultimately designed for officials to administer, the group also makes CHUBE, a version sold directly to consumers wishing to monitor their own alcohol levels. Akers claims this could significantly reduce the rate of alcohol-fuelled accidents.

Moving away from alcohol, but sticking with breathalysers, the group also makes Metron, a device designed to detect levels of ketones in breath condensate. This indicates whether an individual is burning fat as an energy source and to what extent diet and exercise are delivering efficient fat-burning results.
Akers makes several products designed to deliver rapid results for a number of issues: cholesterol levels, free radical damage, malaria and dengue fever are just a few. The breathalyser devices are designed from Akers’s patented biosensor technology, while some of the

more sophisticated devices use technology that filter micro-particles in response to antibody or antigen bindings."

[rivaldo] 18/6/2015 15:19

Patience WW! It's when companies are on the cusp of finally making money after a long wait that investors can see the greatest returns. Re-ratings can happen extremely quickly.

Q2 should see an improvement, but I'm expecting that Q3 onwards - July to September - will see a noticeable improvement, since that's what we've been led to believe. There's no point in moaning until then, as at that point there will genuinely be reason to complain - or celebrate.

Above all, AKR has a very low m/cap which is largely covered by its cash pile and is already selling products, so the downside should in theory be low compared to the potential upside assuming things go reasonably well.

[werewolfie] 17/6/2015 22:22

I dont mean to be BellWhiff but ......

I'm refusing to gamble any more on loss making companies maybe making a profit.what else can you call buying into Akers? After 25 years, we are still told its just around the corner

Ive changed my trading strategy - to decent companies who actually make money.AGA Rangemaster has soared today on the rumour of a takeover. Quantum Pharma has floated on AIM but are pushing to get into the main market. I bought at 1.29 and it hit 1.72 yesterday

Rivaldo - your last post isn't bad news but I will ask the same question- when is this going to translate into sales and profit?

[rivaldo] 16/6/2015 14:46

News just out:



This sounds encouraging for Q3 onwards:

""The response to the Akers Wellness products has been overwhelmingly positive," said Raymond F. Akers, Jr. PhD, Co‐founder and Executive Chairman. "Participation at the Congress was designed to raise awareness of these new tools to assist in weight loss and anti-aging programs, and to gather customer feedback, but in fact it resulted in several hundred reservations for products once commercial production begins in Q3," continued Dr. Akers."

[vancoillie] 11/6/2015 14:57

Yeterday a upgrade to hold from thestreet. Less than half hour trading and a volume of 32000, hopely they hold their gain and not just before closing a drop like many times before. Nice day everyone :)

[mcmather] 08/6/2015 08:54

Waylander, re "Seems like the gravy train just keeps on running"; correct. The following is about 8-10 years old.

Rep. Rob Andrews (NJ-1) requests $20,000,000 for:
Akers Biosciences Inc. 201 Grove Road, Thorofare, NJ 08086:




The figures in Q1 2015 were an absolute disgrace. Dr Raymond Akers Jr and those associated with him should be thoroughly ashamed by such efforts.

Been a bit busy of late but should be able to spend a bit more time highlighting the antics of these clowns - appreciate that their motives may be nothing more than simple greed and trying to come across as being smart - shortly.

[brucie5] 06/6/2015 11:51

Well, it's a promising chart situation for those already attracted to the fundamentals.

[werewolfie] 06/6/2015 08:32

Ok - he is a very capable man who looks like he has left a position under a cloud.

But back to the essential question - when will all these talented people and great products and 25 years of faffing around transform into profit?

Ive invested in Akers for last 2.5 years and the share price has hardly moved - all im hearing is that success is just round the corner. I now believe Ive a made a fundamental mistake - buying into a loss making company (with a real history of losses) in the hope its fortunes will change. I will keep an open mind but....

There are many other small companies on the stock market who are actually achieving? ie/ Quantum Pharma have recently listed on the stock market to real success - they have bought a smaller company called Lamda and are actually making a profit. The share price is rising steadily and the prospects are good. So much that Naked Trader himself Robbie Burns has jumped on board

Time to rethink my strategy....................

[rivaldo] 05/6/2015 23:42

You must have missed this paragraph....

"Upon his departure from the House, President Obama praised his service as "an original author of the Affordable Care Act…and a vital partner in its passage and implementation"

And:

"In the U.S. House of Representatives, Mr. Andrews served on the Committee on Armed Services, Committee on the Budget, and Committee on Education and Labor, where he served as chairman of the Subcommittee on Health, Employment, Labor, and Pensions"

[waylander2] 05/6/2015 20:51

Seems like the gravy train just keeps on running. This seems like a strange appointment to me, I am sure that Rob was useful when he was a congressman but not sure what benefit he brings now.

I got this from Wikipedia' "On February 4, 2014, sources familiar with Andrews' plans indicated that he would resign from Congress to take a position at a Philadelphia law firm. He was under investigation by the House Ethics Committee at the time of his resignation.[2] Andrews retired from the House with the 10th longest tenure among U.S. Representatives in New Jersey history, and the fifth longest among Democrats in his state.[3]" [2] hxxp://www.washingtonpost.com/blogs/post-politics/wp/2014/02/04/n-j-democrat-rob-andrews-expected-to-resign-from-congress/

I am not sure what value he adds to Akers?

[werewolfie] 05/6/2015 19:29

25 years and we are still waiting to see this "impressive" stuff turn into sales and profit

Im getting very concerned now in light of the poor results for Q1. And no profit since 2008

[rivaldo] 29/5/2015 08:20

Good to see AKR presenting and spreading the word in the USA (and not through Redchip either!) on June 2nd:

[rivaldo] 25/5/2015 19:37

Good article, thanks vancoillie - and a nice, balanced conclusion:

"I believe Akers offers an excellent opportunity for risk-tolerant investors who love speculating on health care stocks. AKER's PIFA technology has resulted in a test which can reduce the health care costs of Heparin users with a market opportunity in the hundreds of millions.

The company has only 5.1 million shares outstanding and a strong balance sheet which ensures there will be no need to finance in the near-term. Should the company come out with strong future earnings reports or have another positive development either with its products, technology or a corporate action, the stock can soar. The downside risk is that the company fails to capture market share or the interest of the health care community with its Heparin test or other products. Reading the company's conference call transcripts has me believe Akers is doing the right thing to maximize the possibility of its success.

While Q1 growth was disappointing, Akers has been calling for big things to come in Q2 and Q3, without actually forecasting numbers. It won't be too long before the company releases those results so investors who aren't convinced of the story at this time should still keep an eye on the stock over the next several months."

[norbus] 21/5/2015 06:56

If you believe that , you should put down a deposit on a big yacht

[vancoillie] 20/5/2015 20:44

Thanks, bought begin September , half December and now again, and i will wait till next year to see if there is a future for Akers,

[norbus] 20/5/2015 16:41

Go ahead punk, Make my day ;-)

[vancoillie] 20/5/2015 14:20

When It end higher today, and with a good volume, then It's a buy for me

[rivaldo] 14/5/2015 12:37

Mcmather, I also posted at the time that - and as is pointed out in the RNS - the sales force were not recruited in Q1 and would only impact during Q2 and then properly in Q3.

Please do not take any info I post out of its context.

I understand your and Norbus' frustrations as much longer-term investors than me, but the lack of balance doesn't do your case any good.

As I said, the Q2 and Q3 results will be much more informative. Then will be the time to see if promises have been delivered - or not!

[norbus] 14/5/2015 11:13

Groundhog day

[mcmather] 14/5/2015 10:14

Rivaldo, this is copied from your post on here 22 April 2015 #2847:

- 10 new sales reps are each opening 3 new hospital/customer accounts per month, each selling $30k per annum, which I calculate to be $10.8m revenues per annum once a year's selling is up and running.

The clowns that form Akers' management team have just managed to muster $510,047 revenue from all commercialised products in the first 3 months of 2015! And this having used nearly $6m of the money raised in the IPO 12 months ago!?

[mcmather] 14/5/2015 10:06

Q3 2014 Results:

Revenue for the third quarter totaled $453,313 (Q3 2013: $344,709), a 32% increase from the same period in 2013, primarily driven by sales of PIFA Heparin/PF4 Rapid Assay products in the US.

Q1 2015 results:

Revenue for Q1 2015 was $510,047 (Q1 2014: $1,173,919, of which $766,379 related to alcohol breathalyzer business from ChubeWorkx Guernsey Limited which contributed nil in Q1 2015).


The performance of Akers Biosciences and their management team, since the Nasdaq IPO, has been lamentable.